AISDTS is a prospective registry study, in which clinical information, examination and imaging data of patients with acute ischemic stroke receiving different treatment strategies were collected, grouped and statistically analyzed, and corresponding clinical prediction models were constructed to explore the role of clinical biological indicators in the occurrence and development of stroke.
A) ≥18 years of age; B) hospital admission for ischemic stroke; C) Signed informed consent.
A) patients with incomplete clinical information; B) hospitalization observation time less than 24 hours; C) recent trauma, severe inflammation, severe liver and kidney dysfunction, progressive malignance and other serious diseases; D) baseline mRS score>2; E) informed consent is not signed.
Patients admitted to hospital for ischemic stroke were enrolled.
Cohort
Prospective
Not listed
6
Trial groupsSee each trial group below.
To assess the changes of prognosis of stroke patients under different treatment strategies
assessed by The Modified Rankin Score (mRS) of stroke patients \[mild to wores ranging from 0 to 5, 6 represents death\].
To assess the early neurological changes of ischemic stroke
change from baseline National Institute of Health stroke scalescore (NIHSS) \[higher scores mean worse conditions\]7 days or 14 days
To assess the incidence of recurrent stroke under different treatment strategies
record and analyze the incidence of recurrent stroke from 7 days-24 months
To assess the types and incidence of adverse events of ischemic stroke patients
adverse reactions (hemorrhage, embolus shedding, gastrointestinal ulcer) and stroke-related complications under different treatment strategies
To assess the correlation of RNA/DNA and age factor in acute ischemic stroke
DNA and RNA extracted from peripheral blood samples
To assess the therapeutical effects of Edaravone dexborneol on inflammation and prognosis after acute ischemic stroke
The Modified Rankin Score score (mRS) of stroke patients \[mild to wores ranging from 0 to 5, 6 represents death\].
Click on the lead sponsor to view all of their trials.
